INmune Bio, Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
8.04
-0.20 (-2.43%)
Apr 24, 2025, 4:00 PM EDT - Market closed
INmune Bio Employees
As of December 31, 2024, INmune Bio had 22 total employees, including 13 full-time and 9 part-time employees. The number of employees increased by 5 or 29.41% compared to the previous year.
Employees
22
Change (1Y)
5
Growth (1Y)
29.41%
Revenue / Employee
$636
Profits / Employee
-$1,912,818
Market Cap
184.36M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
INMB News
- 10 days ago - INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom™ Manufacturing for Commercial Readiness - GlobeNewsWire
- 4 weeks ago - INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update - GlobeNewsWire
- 4 weeks ago - Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West + - Seeking Alpha
- 5 weeks ago - INmune Bio: CORDstrom Is A Game-Changer, As Investors Await Alzheimer's Results - Seeking Alpha
- 2 months ago - INmune Bio Opens Phase II in High Dose Cohort of INKmune™ Trial in Prostate Cancer - GlobeNewsWire
- 2 months ago - INmune Bio Announces Plan to Submit FDA Biologics License Application (BLA) Seeking Approval of CORDStrom for Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB) - GlobeNewsWire
- 4 months ago - INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 - Seeking Alpha